Pacific Biosciences of California, Inc.
DB:P09 Stock Report
Pacific Biosciences of California Future Growth
Future criteria checks 1/6 Pacific Biosciences of California is forecast to grow earnings and revenue by 33.4% and 19.5% per annum respectively. EPS is expected to grow by 35.6% per annum. Return on equity is forecast to be -33.7% in 3 years.
Key information
33.4%
Earnings growth rate
Life Sciences earnings growth 26.4% Revenue growth rate 19.5% Future return on equity -33.7% Analyst coverage Good
Last updated 12 Nov 2024
Recent future growth updates
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024 Apr 16 Pacific Biosciences of California, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2022
Pacific Biosciences of California, Inc. Withdraws its Financial Guidance Oct 27
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Full Year 2022 Aug 04
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Fourth Quarter and the Fiscal Year Ended December 31, 2021 Jan 12
Show all updates
Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 3Q 2023) Nov 09
PacBio Unveils the Vega System Nov 07
PacBio Announces SPRQ Chemistry for Revio Sequencing Systems Oct 29
Pacific Biosciences of California, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 11
President recently sold €155k worth of stock Sep 19
Chief Operating Officer recently sold €57k worth of stock Aug 22 Pacific Biosciences of California, Inc. Reports Goodwill Impairment for the Second Quarter Ended June 30, 2024 Aug 08
Pacific Biosciences of California, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 16
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2500 Growth Index Jul 03
First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.36 loss in 1Q 2023) May 11
Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024 May 01
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024 Apr 16
PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions Mar 12
Insider recently bought €162k worth of stock Mar 07
Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022) Mar 04
President recently sold €445k worth of stock Feb 25
Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022) Feb 16
Pacific Biosciences of California, Inc Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale Feb 05
Pacific Biosciences of California, Inc. to Report Q4, 2023 Results on Feb 15, 2024 Jan 26
PacBio Announces New Nanobind Pandna Kit Enabling Hifi Optimized Dna Extraction Solutions Jan 15
Chief Operating Officer recently sold €221k worth of stock Jan 12
Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board Dec 12
PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders Nov 04
Third quarter 2023 earnings released: US$0.26 loss per share (vs US$0.34 loss in 3Q 2022) Nov 01
Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee Oct 28
Pacific Biosciences of California, Inc. Appoints David Meline to its Board of Directors Oct 17
Pacific Biosciences of California, Inc. to Report Q3, 2023 Results on Oct 30, 2023 Oct 13
Pacbio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis Oct 12
President recently sold €918k worth of stock Sep 21
Chief Operating Officer recently sold €263k worth of stock Aug 20
Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for approximately $110 million. Aug 04
Second quarter 2023 earnings released: US$0.28 loss per share (vs US$0.32 loss in 2Q 2022) Aug 03 Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for $110 million.
Pacific Biosciences of California, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 22
Now 25% undervalued Jun 16 Pacific Biosciences of California, Inc. Announces Board Changes
VP & Chief Accounting Officer recently sold €60k worth of stock May 23
Insufficient new directors May 09
Full year 2022 earnings released: US$1.40 loss per share (vs US$0.89 loss in FY 2021) Feb 19
PacBio to Expand MAS-Seq Technology to 16S rRNA and Bulk RNA-Seq Solutions Feb 08
Pacific Biosciences of California, Inc. to Report Q4, 2022 Results on Feb 16, 2023 Feb 03
Insufficient new directors Jan 26 Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million. Jan 26
Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million. Jan 25
Pacific Biosciences of California, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2022
Pacific Biosciences of California, Inc. Announces Board Appointments Nov 03
Pacific Biosciences of California, Inc. Withdraws its Financial Guidance Oct 27 Pacific Biosciences of California, Inc. to Report Q3, 2022 Results on Nov 07, 2022
PacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA Discovery Oct 21
PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing Oct 20
Chief Financial Officer recently sold €75k worth of stock Oct 04
PacBio Unveils A New Method for Comprehensive, Genome-Wide Tandem Repeat Analysis Sep 28
Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.21 loss in 2Q 2021) Aug 04
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Full Year 2022 Aug 04
Pacific Biosciences of California, Inc. Appoints Jeff Eidel as Chief Commercial Officer, Effective August 16, 2022 Jul 22
Pacific Biosciences of California, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 19
Pacific Biosciences of California, Inc. Announces Management Changes May 19
First quarter 2022 earnings released: US$0.37 loss per share (vs US$0.45 loss in 1Q 2021) May 06
Insufficient new directors Apr 27
Pacific Biosciences of California, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 21
Pacific Biosciences of California, Inc., Annual General Meeting, May 25, 2022 Apr 15
Insufficient new directors Apr 05
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 16
Pacific Biosciences of California, Inc. to Report Q4, 2021 Results on Feb 15, 2022 Feb 02
Chief Operating Officer recently sold €519k worth of stock Jan 14
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Fourth Quarter and the Fiscal Year Ended December 31, 2021 Jan 12
PacBio’s New HiFiViral Surveillance Kit Performance is Not Impacted by Omicron Mutations, Delivering Complete SARS-CoV-2 Genomes for All Circulating Variants Dec 29
Insufficient new directors Dec 06
Third quarter 2021 earnings released: EPS US$0.082 (vs US$0.14 loss in 3Q 2020) Nov 03 Pacific Biosciences of California, Inc. (NasdaqGS:PACB) completed the acquisition of Omniome, Inc.
Pacific Biosciences of California, Inc. (NasdaqGS:PACB) acquired Circulomics, Inc. Aug 05
Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.15 loss in 2Q 2020) Aug 04
Senior Fellow & Director Michael Hunkapiller has left the company Jun 18
VP & Chief Accounting Officer has left the company May 19
First quarter 2021 earnings released: US$0.45 loss per share (vs US$0.008 profit in 1Q 2020) May 01
Pacific Biosciences of California, Inc. Launches New HiFi Sequencing Workflow Apr 27
Revenue beats expectations Mar 02
Full year 2020 earnings released: EPS US$0.18 (vs US$0.55 loss in FY 2019) Mar 02
VP & Chief Accounting Officer recently sold €124k worth of stock Feb 27
Pacific Biosciences Sequel II Systems Deployed to Scale-Up Global Viral Surveillance Initiatives Focused on COVID-19 Feb 19
Independent Director recently sold €4.2m worth of stock Feb 19
Pacific Biosciences of California, Inc. announced that it has received $900 million in funding from SB Northstar LP Feb 18
Full year 2020 earnings released: EPS US$0.18 (vs US$0.55 loss in FY 2019) Feb 12
Revenue beats expectations Feb 12
New 90-day high: €42.00 Feb 12
Pacific Biosciences of California, Inc. announced that it expects to receive $900 million in funding from SB Northstar LP Feb 11
Pacific Biosciences of California, Inc., Annual General Meeting, Jun 16, 2021 Feb 10
Senior Fellow & Director recently sold €1.5m worth of stock Jan 24
Earnings and Revenue Growth Forecasts DB:P09 - Analysts future estimates and past financials data (USD Millions) Date Revenue Earnings Free Cash Flow Cash from Op Avg. No. Analysts 12/31/2026 258 -169 -86 -43 12 12/31/2025 193 -202 -122 -108 14 12/31/2024 157 -359 -250 -184 14 9/30/2024 173 -394 -240 -233 N/A 6/30/2024 189 -400 -261 -253 N/A 3/31/2024 200 -297 -249 -240 N/A 12/31/2023 201 -307 -268 -259 N/A 9/30/2023 170 -309 -274 -262 N/A 6/30/2023 146 -319 -275 -260 N/A 3/31/2023 134 -321 -296 -279 N/A 12/31/2022 128 -314 -280 -263 N/A 9/30/2022 137 -299 -249 -234 N/A 6/30/2022 140 -206 -224 -212 N/A 3/31/2022 135 -175 -176 -167 N/A 12/31/2021 131 -181 -117 -111 N/A 9/30/2021 122 -37 -97 -94 N/A 6/30/2021 106 -77 -73 -71 N/A 3/31/2021 92 -59 -80 -79 N/A 12/31/2020 79 29 18 20 N/A 9/30/2020 80 -46 14 16 N/A 6/30/2020 83 -51 15 16 N/A 3/31/2020 90 -53 21 22 N/A 12/31/2019 91 -84 -81 -78 N/A 9/30/2019 82 -115 -82 -79 N/A 6/30/2019 79 -111 -78 -76 N/A 3/31/2019 76 -109 -76 -73 N/A 12/31/2018 79 -103 -68 -66 N/A 9/30/2018 84 -93 -71 -68 N/A 6/30/2018 89 -90 N/A -71 N/A 3/31/2018 88 -93 N/A -70 N/A 12/31/2017 93 -92 N/A -68 N/A 9/30/2017 94 -90 N/A -60 N/A 6/30/2017 96 -86 N/A -58 N/A 3/31/2017 97 -79 N/A -64 N/A 12/31/2016 91 -74 N/A -68 N/A 9/30/2016 101 -57 N/A -56 N/A 6/30/2016 90 -37 N/A -56 N/A 3/31/2016 94 -31 N/A -44 N/A 12/31/2015 93 -32 N/A -48 N/A 9/30/2015 73 -49 N/A -63 N/A 6/30/2015 80 -60 N/A -53 N/A 3/31/2015 67 -67 N/A -59 N/A 12/31/2014 61 -66 N/A -51 N/A 9/30/2014 53 -64 N/A -51 N/A 6/30/2014 40 -76 N/A -26 N/A 3/31/2014 34 -77 N/A -29 N/A 12/31/2013 28 -79 N/A -30 N/A
Show more
Analyst Future Growth Forecasts
Earnings vs Savings Rate: P09 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: P09 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: P09 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: P09's revenue (19.5% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: P09's revenue (19.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: P09 is forecast to be unprofitable in 3 years.
Discover growth companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}